Julian Adams discusses Gamida Cell’s NAM technology to develop two of its lead clinical programs by expanding blood forming stem and progenitor cells from umbilical cord blood to create highly functional, stand-alone grafts that serve as a universal bone marrow transplant solution.

Gamida Cell has successfully harnessed its NAM platform technology to leverage the advantages of cord blood and overcome its limitations by increasing the number of CD34+ stem and progenitor cells, while enhancing their homing and engraftment efficiency.